retatrutide phase 3 2025 triple agonist glp-1 gip glucagon Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset: Strong, Mike: 9798268084771 Books Lilly's triple agonist achieves 16.8%

Rondanelli M, Perna S, Riva A, Petrangolini G, Di Paolo E, Gasparri C

Cognitive and behavioral problems might also manifest

It plays a vital role in stimulating insulin secretion, slowing gastric emptying, and reducing appetite, thus helping maintain balanced blood sugar levels and supporting weight management

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Ongoing research into oral semaglutide and other peptide delivery technologies promises to make this segment increasingly competitive in the coming years

While some previous studies reported I values or mentioned heterogeneity, they lacked robust sensitivity testing across all outcomes